Evaluating Novavax (NVAX) Valuation As Licensing Deal And Recent Returns Shape Market Expectations

Recent share performance and what it may signal for investors

Novavax (NVAX) has seen mixed share performance recently, with a 5.6% decline over the past day and a 12.2% decline over the past week, in contrast to a 23.9% gain over the past 3 months.

See our latest analysis for Novavax.

At a share price of US$8.45, Novavax has recently seen weaker short term share price returns but a positive year to date share price return and positive multi year total shareholder returns, which suggests sentiment has been improving after a difficult longer run.

If you are comparing Novavax with other healthcare names pushing the boundaries of AI in medicine, it can be useful to scan a wider field using the 34 healthcare AI stocks

With Novavax trading at US$8.45 and sitting at what appears to be a sizable discount to both analyst targets and some intrinsic estimates, investors now face a key question: is this a genuine buying opportunity or is the market already pricing in future growth?

Most Popular Narrative: 38.7% Undervalued

At a last close of $8.45 versus a narrative fair value of $13.78, the most followed story around Novavax argues the market is heavily discounting future cash flows given a 7.34% discount rate.

The license agreement with Pfizer, including a US$30m upfront payment and high mid single digit royalties on products containing Matrix M, adds a defined cash inflow and a potential recurring royalty stream that can support enterprise value beyond the core COVID vaccine business.

Read the complete narrative.

Want to see what sits behind that valuation gap? The narrative focuses on shrinking revenues, changing profit margins, and a punchy future earnings multiple that hinges on key licensing economics.

Result: Fair Value of $13.78 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you still need to weigh the heavy dependence on partner driven royalties and COVID related vaccines, because any stumble in these areas could quickly challenge this undervalued story.

Find out about the key risks to this Novavax narrative.

Next Steps

With sentiment split between upside potential and clear risks, it makes sense to move quickly, review the numbers yourself, and decide where you stand by weighing the 3 key rewards and 5 important warning signs.

Looking for more investment ideas?

If Novavax has caught your attention, do not stop there. Use the Simply Wall Street Screener to quickly spot other opportunities that fit the way you like to invest.

• Hunt for quality at a discount by scanning 62 high quality undervalued stocks that combine strong fundamentals with prices that look compelling.
• Target resilience first by reviewing 64 resilient stocks with low risk scores that score well on business stability and balance sheet strength.
• Get ahead of the crowd by checking the screener containing 25 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com